MedPath

Acelyrin's Izo Fails Phase 2b/3 Trial in Uveitis; Wells Fargo Adjusts Price Target

• Acelyrin's Phase 2b/3 trial of izokibep (izo) in uveitis has failed, leading to the removal of its contribution from Wells Fargo's financial model. • Wells Fargo has lowered its price target for Acelyrin from $15 to $13, while maintaining an Overweight rating on the shares. • The firm believes the downside impact on Acelyrin's stock will be limited due to the market not assigning significant value to the uveitis program.

Acelyrin (SLRN) has announced the failure of its Phase 2b/3 trial evaluating izokibep (izo) for the treatment of uveitis. The news prompted Wells Fargo to lower its price target on Acelyrin shares from $15 to $13, while reaffirming an Overweight rating. According to the firm, the unsuccessful trial outcome should have a limited negative impact on the stock, as the market had not previously factored in substantial value for the izokibep uveitis program.
Wells Fargo is removing the izokibep uveitis contribution from its financial model, indicating that the drug will not be developed further for this indication. The analyst note suggests a strategic shift away from uveitis following the trial results.

Impact on Acelyrin's Pipeline

The failure in uveitis does not impact Acelyrin's other ongoing clinical programs. The company is focusing on other indications for izokibep, including hidradenitis suppurativa and psoriatic arthritis. Further updates on these programs are anticipated in the coming months.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Wells Fargo Lowers Intellia Therapeutics Price Target to $60

Wells Fargo has reduced its price target for Intellia Therapeutics from $70 to $60, maintaining an Overweight rating. The adjustment follows the discontinuation of the Alpha-1 Antitrypsin Deficiency program, with the firm highlighting ATTR amyloidosis with cardiomyopathy as the primary value driver.

Promising Phase 1/2 Results for ACELYRIN's Lonigutamab Support Buy Rating

Derek Archila from Wells Fargo maintains a Buy rating on ACELYRIN, INC. due to promising Phase 1/2 trial results for Lonigutamab, indicating potential safety advantages and sufficient activity to advance to Phase 3 trials.

Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease with Optimized Dosing Strategy

Acelyrin's lonigutamab Phase 1/2 study update reveals that lower doses administered every four weeks were subtherapeutic for thyroid eye disease (TED).
The company's analysis determined that a minimum concentration of 3 ug/ml is required for maximized efficacy, achievable with a 100 mg loading dose followed by 50 mg every two weeks.

Acelyrin's Lonigutamab Shows Promise in Thyroid Eye Disease Phase 2 Data

Acelyrin will present Phase 2 data for subcutaneous Lonigutamab, indicating a potentially best-in-class efficacy and safety profile for Thyroid Eye Disease (TED).
The company plans to unveil the design for its Phase 3 program following a successful meeting with the FDA.

Intellia Therapeutics Price Target Lowered by Wells Fargo

Wells Fargo has reduced the price target for Intellia Therapeutics from $80 to $70, while maintaining an Overweight rating on the shares, citing promising Phase 1 ATTR-CM data for nex-z.

Allogene Pauses Cema-Cel Trial Enrollment, Prioritizes Other Programs

Allogene Therapeutics halts new patient enrollment in the Phase 1 ALPHA2 study of cema-cel for relapsed/refractory Chronic Lymphocytic Leukemia (r/r CLL) due to slow enrollment.
Piper Sandler reduces Allogene's price target to $9, excluding cema-cel revenue in CLL from its valuation model, while maintaining an Overweight rating.

Acelyrin Re-prioritizes Pipeline After Mixed Izokibep Results, Shifts Focus to Lonigutamab

Acelyrin's Phase 3 trial of izokibep for hidradenitis suppurativa (HS) met its primary endpoint, with 33% of patients achieving HiSCR75 at Week 12 compared to 21% on placebo.
Despite positive results, Acelyrin will not advance izokibep for HS or psoriatic arthritis (PsA) due to competitive concerns and insufficient efficacy.

Acelyrin Shifts Focus to Thyroid Eye Disease Drug, Halts Further Investment in Izokibep

Acelyrin will discontinue development of izokibep for hidradenitis suppurativa and psoriatic arthritis despite positive trial data, due to strategic prioritization.
The company will now focus on lonigutamab, an experimental antibody treatment for thyroid eye disease, advancing directly to Phase 3 trials.

Acelyrin's Izokibep Clinical Trial Faces Dosing Error, Top-Line Psoriatic Arthritis Data Expected Q1 2024

Acelyrin's psoriatic arthritis trial (PsA) experienced a dosing sequence error due to incorrect programming by Clinical Research Organization Fortrea, affecting some patients in specific dosing arms.
The error, involving the 160mg Q2W and 80mg Q4W dosing arms, resulted in patients receiving placebo and active treatment in a random order, though no patient received more active ingredient than allowed.

Acelyrin's Izokibep Fails to Meet Primary Endpoint in Phase 2b/3 Psoriasis Trial, Stock Plummets

Acelyrin's stock price plummeted after its investigational drug, izokibep, failed to achieve the primary endpoint in a Phase 2b/3 clinical trial for moderate-to-severe psoriasis.
The trial results were described as "painfully disappointing" by analysts, leading to a significant reduction in the company's price target by Jefferies.

Reference News

[1]
Acelyrin price target lowered to $13 from $15 at Wells Fargo - TipRanks.com
tipranks.com · Dec 11, 2024

Wells Fargo reduced Acelyrin's (SLRN) price target to $13 from $15, maintaining an Overweight rating. The adjustment fol...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy